The angiotensin-converting-enzyme insertion/deletion polymorphism is not related to venous thrombosis

Herwig Köppel; Wilfried Renner; Alexander Gugl; Lisa Cichocki; Robert Gasser; Thomas C.Wascher; Ernst Pilger

doi:10.1160/TH03-05-0266

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2004; 91(01): 76-79
DOI: 10.1160/TH03-05-0266

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

The angiotensin-converting-enzyme insertion/deletion polymorphism is not related to venous thrombosis

Authors

Herwig Köppel

¹Division of Angiology, Karl-Franzens University Graz, Austria
Wilfried Renner

⁴Clinical Institute for Medical and Chemical Laboratory Diagnostics, Department of Medicine, Karl-Franzens University Graz, Austria
Alexander Gugl

¹Division of Angiology, Karl-Franzens University Graz, Austria
Lisa Cichocki

²Division of Cardiology, Karl-Franzens University Graz, Austria
Robert Gasser

²Division of Cardiology, Karl-Franzens University Graz, Austria
Thomas C.Wascher

³Researchgroup for Diabetic Angiopathy, Karl-Franzens University Graz, Austria
Ernst Pilger

¹Division of Angiology, Karl-Franzens University Graz, Austria

Abstract

Summary

The insertion/deletion (I/D) polymorphism of the gene for angiotensin-converting-enzyme (ACE) is associated with ACE plasma levels and activity. Conflicting results have been reported about the relevance of this polymorphism for venous thrombosis. The aim of the present study was to analyze the role of this polymorphism for deep venous thrombosis. The study was designed as a case-control study, including 330 patients with documented deep venous thrombosis and 354 controls. ACE genotype was determined by size-analysis of polymerase chain reaction products. Results showed that, ACE genotype frequencies were similar between patients (II: 24.8%; ID: 43.3%; DD: 31.8%) and controls (II: 22.9%; ID: 50.6%; DD: 26.6%, P = 0.15).The adjusted odds ratio of carriers of the DD genotype for venous thrombosis was 1.24 (95% confidence interval 0.90–1.80).The polymorphism was furthermore not associated with age at first thromboembolic event or the occurrence of pulmonary embolism. From these results, we can conclude that the ACE I/D polymorphism is not a significant risk factor for deep venous thrombosis.

Keywords

Angiotensin-converting-enzyme - polymorphism - genetics - venous thromboembolism

Full Text

References

References
1 Vaughn DE. The renin-angiotensin system and fibrinolysis. Am J Cardiol 1997; 79: 12-6.
2 Chabielska E, Pawlak R, Buczko W. Effects of drugs affecting the renin-angiotensin system on venous thrombosis in normotensive rats. Pol J Pharmacol 1996; 48: 89-91.
3 Pawlak R, Chabielska E, Buczko W. Antithrombotic effect of enalapril, an angiotensinconverting enzyme inhibitor, on venous thrombosis in rats. Pol J Pharmacol 1996; 48: 117-20.
4 Rigat B, Hubert C, Alhenc-Gelas F. et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6.
5 Tiret L, Rigat B, Visvikis S. et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51: 197-205.
6 Philipp CS, Dilley A, Saidi P. et al. Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty. Thromb Haemost 1998; 80: 869-73.
7 Dilley A, Austin H, El-Jamil M. et al. Genetic factors associated with thrombosis in pregnancy in a United States population. Am J Obstet Gynecol 2000; 183: 1271-7.
8 Dilley A, Austin H, Hooper WC. et al. Relation of three genetic traits to venous thrombosis in an African-American population. Am J Epidemiol 1998; 147: 30-5.
9 Jackson A, Brown K, Langdown J. et al. Effect of the angiotensin-converting enzyme gene deletion polymorphism on the risk of venous thromboembolism. Br J Haematol 2000; 111: 562-4.
10 Della MD, Valle CJ, Issack PS, Baitner A. et al. The relationship of the factor V Leiden mutation or the deletion-deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty. BMC Musculoskelet Disord 2001; 02: 1.
11 Gonzalez AJOrdonez, Fernandez JMCarreira, Medina JMRodriguez. et al. Risk of venous thromboembolism associated with the insertion/deletion polymorphism in the angiotensin-converting enzyme gene. Blood Coagul Fibrinolysis 2000; 11: 485-90.
12 Renner W, Koppel H, Hoffmann C. et al. Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu: common mutations of blood coagulation factors and deep vein thrombosis in Austria. Thromb Res 2000; 99: 35-9.
13 Friedl W, Krempler F, Paulweber B. et al. A deletion polymorphism in the angiotensin converting enzyme gene is not associated with coronary heart disease in an Austrian population. Atherosclerosis 1995; 112: 137-43.
14 Colhoun HM, McKeigue PM, Smith GD. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361: 856-72.
15 Ioannidis JPA, Trikalinos TA, Ntzani EE. et al. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003; 361: 567-71.
16 Fatini C, Gensini F, Sticchi E. et al. ACE DD genotype: an independent predisposition factor to venous thromboembolism. Eur J Clin Invest 2003; 33 (08) 642-7.
17 Von Depka M, Czawalinna A, Wermes C. et al. The deletion polymorphism in the angiotensin-converting enzyme gene is a moderate risk factor for venous thromboembolism. Thromb Haemost 2003; 89 (05) 847-52.